A new, national survey of adult epilepsy patients, caregivers and healthcare professionals (HCPs) revealed a wide range of challenges in the management of epilepsy, which affects more than three million adults in the United States.1 SK Life Science, Inc. engaged Kantar Health to develop the Seize the Truth about Epilepsy Perceptions (STEP) … Read More
The “Seize the Truth About Epilepsy Perceptions” (STEP) Survey was conducted online on behalf of SK Life Science, Inc. The results revealed important disconnects that exist between patients, caregivers and healthcare providers (HCPs).
DYK? SUDEP is the most common disease-related cause of death in people with epilepsy. By having early conversations and educating patients and families on #SUDEP, we can work with them on the modifiable risk factors (AEDs adherence and adverse events). Read more on the connection between patient education and seizure freedom.
Lili was diagnosed with Lennox-Gastaut syndrome (LGS), a rare and severe form of epilepsy, but therapeutic horseback riding was an activity she could enjoy.
Mark your calendar for the online event this Saturday May 6, 10am-6pm pst ( 1-9pm est ) , the “TALK ABOUT IT for Epilepsy” Netathon
Sunovion Pharmaceuticals Inc. (Sunovion) announced on August 28, 2015 that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for Aptiom® (eslicarbazepine acetate) as monotherapy for the treatment of partial-onset seizures.